(Q36057816)

11 August 2017

1 reference

title

Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment (English)

1 reference

11 August 2017

0 references

1 reference

1

Masakazu Toi

1 reference

11 August 2017

author name string

Mohammad Atiqur Rahman

series ordinal

2

1 reference

11 August 2017

Hiroko Bando

series ordinal

3

1 reference

11 August 2017

Louis W C Chow

series ordinal

4

1 reference

11 August 2017

publication date

1 March 2005

1 reference

Lancet Oncology Commission

11 August 2017

published in

1 reference

11 August 2017

volume

6

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

158-166

1 reference

Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Angiogenic activity of enzymes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Thymidine phosphorylase inhibits apoptosis induced by cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Expression of the angiogenic factor thymidine phosphorylase in THP-1 monocytes: induction by autocrine tumor necrosis factor-alpha and inhibition by aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Structural properties of 3.0 kb and 3.2 kb transcripts encoding platelet-derived endothelial cell growth factor/thymidine phosphorylase in A431 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Thymidine phosphorylase suppresses Fas-induced apoptotic signal transduction independent of its enzymatic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Prognostic value of thymidine phosphorylase expression in breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

The nucleoside derivative 5'-O-trityl-inosine (KIN59) suppresses thymidine phosphorylase-triggered angiogenesis via a noncompetitive mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: discovery of novel orally active inhibitors of human thymidine phosphorylase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2901766-3

7 January 2021

10.1016/S1470-2045(05)01766-3

Identifiers

DOI

1 reference

11 August 2017

1 reference